ArticleJournal for immunotherapy of cancer2021

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.

Felix Zirngibl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.